Related Experiment Video
Updated: Jul 9, 2026
Orthotopic Implantation of Patient-Derived Cancer Cells in Mice Recapitulates Advanced Colorectal Cancer
Published on: February 10, 2023
Intensified irinotecan-based neoadjuvant chemoradiotherapy in rectal cancer: four consecutive designed studies to
Gunther Klautke1, Ute Küchenmeister, Thomas Foitzik
1Department of Radiotherapy, University Hospital, Sudring 75, Rostock, Germany. gunther.klautke@med.uni-rostock.de
Background:
The objective of the present study was to analyse toxicity and efficacy of irinotecan-based neoadjuvant chemoradiotherapy by the help of four consecutively planed and prospectively performed phase II studies.
Patients And Methods:
Patients with locally advanced rectal cancer received radiotherapy and concurrently chemotherapy consisting 5-Fu/capecitabine in a continuous or intermittent application and irinotecan in two different total doses (240 vs. 200 mg/m(2)).
Results:
Diarrhea CTC grade III was seen in 35% in continuous application of 5-Fu/capecitabine versus 12.5% in intermittent application (p= 0,008). Complete response according to the irinotecan dose during chemoradiotherapy (240 mg/m(2) vs. 200 mg/m(2)) was 24% and 0%.
Conclusions:
Chemoradiotherapy of the last phase II study with intermittent capecitabine (1500 mg/m(2)/day, delivered on days 1-14 and 22-35) and irinotecan (4 x 60 mg/m(2)) concurrently to radiotherapy is a safe treatment with low toxicity and high efficacy.
